The therapeutic landscape of metastatic hormone sensitive and metastatic castration-resistant prostate cancer (mCRPC) is rapidly changing. We reviewed the current treatment options for …

The FDA has granted fast track designation to TRE-515 (Trethera Corporation), a novel drug, in combination with radiation therapy for the treatment of prostate cancer. Specifically, the …

2025年7月10日 · TRE-515 is currently in phase 1 clinical trials for solid tumors. The Fast Track designation applies to TRE-515 in combination with radioligand therapy for the treatment of …

Lutetium-177 (177 Lu)-labelled prostate-specific membrane antigen (PSMA)-targeting radioligand therapy is an established treatment for patients with metastatic castration-resistant prostate …

Pluvicto gains FDA approval for earlier use in mCRPC. Backed by key trials, it shows improved survival and safety in advanced prostate cancer patients.

The treatment landscape of metastatic castrate-resistant prostate cancer (mCRPC) has been dramatically trans-formed over the past two decades by several leapfrog advances including …

2025年7月11日 · The FDA granted fast track designation to TRE-515 plus radioligand therapy for treating PSMA-positive metastatic castration-resistant prostate cancer.

Introduction Metastatic castration-resistant prostate cancer (mCRPC) is an advanced form of prostate cancer and is the second leading cause of cancer-related death among men. …

Radiation oncology is an important piece of that, but I also think it’s very important that other physicians across specialties get excited and interested in the radiopharmaceuticals to come. …

Treatment options for patients with metastatic castration-resistant prostate cancer (mCRPC) include different systemic agents. Both taxane chemotherapy 1 and androgen …